- Home
- CBRL vs MNKD Comparison
CBRL vs MNKD Comparison
Compare CBRL & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBRL | MNKD |
|---|---|---|
| Founded | 1969 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1998 | 2004 |
Fundamental Metrics
Financial Performance| Metric | CBRL | MNKD |
|---|---|---|
| Price | $45.05 | $3.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $36.89 | $8.69 |
| AVG Volume (30 Days) | 774.6K | ★ 2.7M |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | ★ 12.57 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $3,030,445,000.00 | $348,966,000.00 |
| Revenue This Year | N/A | $35.81 |
| Revenue Next Year | $3.56 | $11.89 |
| P/E Ratio | $50.88 | ★ N/A |
| Revenue Growth | 3.56 | ★ 22.23 |
| 52 Week Low | $24.85 | $2.23 |
| 52 Week High | $60.26 | $6.51 |
Technical Indicators
Market Signals| Indicator | CBRL | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 30.10 | 36.26 |
| Support Level | $42.58 | $3.30 |
| Resistance Level | $48.91 | $4.29 |
| Average True Range (ATR) | 2.21 | 0.16 |
| MACD | -1.20 | -0.05 |
| Stochastic Oscillator | 11.83 | 5.81 |
Price Performance
Historical ComparisonAbout CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The Cracker Barrel stores consists of a restaurant with a gift shop. The restaurants serve breakfast, lunch and dinner. The gift shop offers a variety of decorative and functional items specializing in rocking chairs, holiday gifts, toys, apparel and foods.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.